ES2295200T3 - Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar. - Google Patents

Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar. Download PDF

Info

Publication number
ES2295200T3
ES2295200T3 ES01963734T ES01963734T ES2295200T3 ES 2295200 T3 ES2295200 T3 ES 2295200T3 ES 01963734 T ES01963734 T ES 01963734T ES 01963734 T ES01963734 T ES 01963734T ES 2295200 T3 ES2295200 T3 ES 2295200T3
Authority
ES
Spain
Prior art keywords
methyl
phenyl
acid
oxazol
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01963734T
Other languages
English (en)
Spanish (es)
Inventor
Robert J. Ardecky
Dawn Alisa Brooks
Alexander Glenn Godfrey
Sarah Beth Jones
Nathan Bryan Mantlo
James Ray Mccarthy
Pierre-Yves Michellys
Christopher John Rito
John S Tyhonas
Leonard Larry Winneroski
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Eli Lilly and Co
Original Assignee
Ligand Pharmaceuticals Inc
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc, Eli Lilly and Co filed Critical Ligand Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2295200T3 publication Critical patent/ES2295200T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES01963734T 2000-08-23 2001-08-23 Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar. Expired - Lifetime ES2295200T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22745600P 2000-08-23 2000-08-23
US227456P 2000-08-23

Publications (1)

Publication Number Publication Date
ES2295200T3 true ES2295200T3 (es) 2008-04-16

Family

ID=22853183

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01963734T Expired - Lifetime ES2295200T3 (es) 2000-08-23 2001-08-23 Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.

Country Status (10)

Country Link
US (1) US7176224B2 (enExample)
EP (1) EP1313717B1 (enExample)
JP (1) JP2004506722A (enExample)
AT (1) ATE375985T1 (enExample)
AU (1) AU2001284660A1 (enExample)
CA (1) CA2418134A1 (enExample)
DE (1) DE60131001T2 (enExample)
ES (1) ES2295200T3 (enExample)
MX (1) MXPA03001610A (enExample)
WO (1) WO2002016332A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001558A (es) 2000-08-23 2003-06-06 Lilly Co Eli Agonistas del receptor activado del proliferador de peroxisoma.
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
IL158873A0 (en) * 2001-06-07 2004-05-12 Lilly Co Eli Modulators of peroxisome proliferator activated receptors
IL159002A0 (en) * 2001-06-07 2004-05-12 Lilly Co Eli Modulators of peroxisome proliferator activated receptors (ppar)
ES2326411T3 (es) * 2001-10-12 2009-10-09 Nippon Chemiphar Co., Ltd. Activador del receptor delta activado por proliferadores de peroxisomas.
US20050080115A1 (en) * 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
CA2503117C (en) * 2002-11-08 2010-12-21 F. Hoffmann-La Roche Ag Substituted 4-alkoxyoxazol derivatives as ppar agonists
US7192970B2 (en) * 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
BRPI0407180A (pt) 2003-02-14 2006-02-07 Lilly Co Eli Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
DE102004060227B3 (de) * 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
WO2007013694A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
MY156174A (en) 2009-08-05 2016-01-15 Daiichi Sankyo Co Ltd 4-(1,2,4-dioxazol-3-yl)benzamides for the treatment of diabetes and obesity
PL2628733T3 (pl) * 2010-10-14 2015-05-29 Daiichi Sankyo Co Ltd Pochodna acylobenzenu

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1997028115A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Antidiabetic agents
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CZ53699A3 (cs) * 1996-08-19 1999-07-14 Japan Tobacco Inc. Deriváty propionové kyseliny a jejich použití
KR100620337B1 (ko) 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
MXPA03001558A (es) * 2000-08-23 2003-06-06 Lilly Co Eli Agonistas del receptor activado del proliferador de peroxisoma.
CA2420178A1 (en) 2000-08-23 2002-03-07 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists

Also Published As

Publication number Publication date
CA2418134A1 (en) 2002-02-28
EP1313717A1 (en) 2003-05-28
US7176224B2 (en) 2007-02-13
EP1313717B1 (en) 2007-10-17
US20040138277A1 (en) 2004-07-15
AU2001284660A1 (en) 2002-03-04
ATE375985T1 (de) 2007-11-15
DE60131001T2 (de) 2008-07-17
MXPA03001610A (es) 2003-09-10
WO2002016332A1 (en) 2002-02-28
JP2004506722A (ja) 2004-03-04
DE60131001D1 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
ES2288982T3 (es) Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar.
ES2204684T3 (es) Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.
US6930120B2 (en) Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists
ES2295200T3 (es) Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
EP1517882A1 (en) Amide linker peroxisome proliferator activated receptor modulators
US20080207685A1 (en) Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar